 silodosin |
| Rapaflo |
Pharmaceutical
company:
Watson Pharmaceuticals, Inc.
www.rapaflo.com |
Pharmacologic classification: alpha-1 adrenergic receptor antagonist
Therapeutic classification: benign prostatic hyperplasia (BPH) drug
Pregnancy risk category: B
AVAILABLE FORMS
Capsules: 4 mg, 8 mg
INDICATIONS AND DOSAGES
To improve symptoms of BPH—
Men: 8 mg P.O. once daily.
ADJUST-A-DOSE: For patients with a creatinine clearance of 30 to 50 ml/minute, 4 mg once daily.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with severe renal or hepatic impairment and in those taking strong CYP3A4 inhibitors.
INTERACTIONS
Drug-drug.
Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir): May increase silodosin level. Avoid use together.
Moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil): May increase silodosin level. Use together cautiously.
Alpha blockers: May cause interactions. Avoid use together.
Strong P-glycoprotein inhibitors (cyclosporine): May increase silodosin levels. Don't use together.
Antihypertensives: May cause dizziness and orthostatic hypotension. Use together cautiously and monitor patient for adverse reactions.
Drug-food.
Moderate fat and calorie intake: May decrease silodosin concentration. Administer with food to minimize adverse reactions.
ADVERSE REACTIONS
CNS: asthenia, dizziness, headache, insomnia.
CV: orthostatic hypotension.
EENT: nasal congestion, nasopharyngitis, rhinorrhea, sinusitis.
GI: abdominal pain, diarrhea.
GU: retrograde ejaculation.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
